For the treatment of metastatic triple-negative breast cancer (TNBC) in India Roche India has launched Atezolizumab.
The Drug Controller General of India approved it based on the data from phase IIIImpassion130 study which shows that Atezolizumab is proven to significantlyreduce the risk of disease worsening or death (PFS) in the intention-to-treat and PD-L1 positive population with metastatic or unresectable locally advanced triple-negative breast cancer (TNBC).

“Atezolizumab is the first immunotherapy drug to be approved globally and in India for triple negative breast cancer, an aggressive disease with very limited treatment options,” said V Simpson Emmanuel, General Manager, Roche Products. “Roche has been at the forefront of improving the lives of patients diagnosed with breast cancer. This launch further strengthens our commitment to provide better outcomes for patients with unresectable locally advanced and
metastatic triple-negative breast cancer in India.”

Breast cancer impacts almost 2.1 million women each year.